Another factor to consider is whether the potential long term benefits, including weight loss or possible disease improvement, would require continued use of GLP-1 agonist in addition to other IBD treatment options, as this can represent an additional financial or emotional burden on patients.
: L- -L- (ALCAR) L- L- (LCLT) -L- ( GPLC) L- (L-Carnitine)
Ma Y, Deng Y, Li N, Dong A, Li H, Chen S, et al
Microdosing options Some patients find that standard tirzepatide doses produce side effects that are difficult to tolerate
Exploring SGLT2 Inhibitors SGLT2 inhibitors, including empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana), offer a different therapeutic pathway